Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7198457 vs Watchful Waiting in ctDNA+ Resected Stage II/III Colorectal Cancer
NCT04486378Phase 2Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Mar 2021
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 7
01
Overview
A Phase 2 trial of autogene cevumeran in colorectal cancer (CRC), sponsored by BioNTech SE. Started Mar 2021; status: active, not recruiting.
02
Drugs
autogene cevumeran
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04486378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486378.